Nasdaq Stockholm

Abera Bioscience AB

ISIN SE0015245097Filings at the FI

At a glance

Most recent filing on May 18, 2022 — an open-market purchase by Mats Lundgren on May 17, 2022.

We hold 10 visible filings, going back to January 20, 2022.

Filings we could not classify with confidence are set aside for review, so they are in none of these counts.

Insider trades

What is a MAR filing?

5 of 10 shown

This page is free to read, and it stops after 5 rows. Those are the 5 most recent filings at this company, out of 10. Reading the whole list, and the full version of the page each row opens (that page itself opens free, with its first rows), is part of the subscription. So are the price history with every buy marked, the price change beside each line, and any moments with several buyers or buying streaks. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Mats Lundgren Deputy chief executive officer
51,627 SEKOpen-market buy
TradedMay 16, 2022FiledMay 18, 2022
Mats Lundgren Deputy chief executive officer
56,140 SEKOpen-market buy
TradedMay 13, 2022FiledMay 18, 2022
Mats Lundgren Deputy chief executive officer
48,060 SEKOpen-market buy
TradedMay 13, 2022FiledMay 18, 2022
Mats Lundgren Deputy chief executive officer
7,096 SEKOpen-market buy
TradedMay 17, 2022FiledMay 18, 2022
Anders Ericsson Closely associated: Chair of the board
15,860 SEKOpen-market buy
TradedMay 13, 2022FiledMay 17, 2022